IKT · Inhibikase Therapeutics Inc
United States · RS rating 34 · As of 2026-10-14
| Price | 1.80 USD |
|---|---|
| 1-day change | +2.3% |
| RS rating (overall / 1M / 3M / 12M) | 34 / 10 / 31 / 61 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 30 / 29 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -10.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +28.6% |
| Market cap (USD) | $254.8M |